SEATTLE, Oct. 20 /PRNewswire/ -- Immunex Corporation (Nasdaq: IMNX)
announced today the promotions of Robert J. Bettencourt as vice president of
managed care, Edison C. Russell as vice president of specialty therapeutics
sales, and Michael P. Ambielli as senior director of commercial operations.
"These key promotions highlight our focus on managing the business
opportunities of today while planning for future growth and success," said
Peggy Phillips, Immunex chief operating officer. "Creating a
high-performance, efficient commercial structure that leverages our strengths
and identifies opportunities is what helps make Immunex successful."
Bob Bettencourt will serve as vice president of managed care, building
strategic alliances with important managed care business partners. In
addition, Bettencourt will work closely with the Immunex marketing partner for
ENBREL(R) (etanercept), Wyeth-Ayerst, on managed care outreach initiatives.
Wyeth-Ayerst is the pharmaceutical division of American Home Products
Corporation.
Ed Russell takes on the role of vice president, specialty therapeutics
sales, focusing on sales initiatives for LEUKINE(R) (sargramostim),
NOVANTRONE(R) (mitoxantrone for injection concentrate), and other Immunex
specialty therapeutics products. In his previous role as senior director of
managed healthcare at Immunex, Russell was responsible for national accounts
and healthcare policy and reimbursement.
A new commercial operations group has been created, headed by Mike
Ambielli, who will serve as senior director. This group will provide support
to both the specialty therapeutics and ENBREL(R) franchises. Ambielli will
oversee management of marketing communications and marketing research,
contracts and pricing, sales administration, and customer service functions.
Additional responsibilities include strategic pricing programs as well as
evaluation and analysis of business proposals from the field sales
organization.
"We're centralizing terrific internal resources to serve both the
specialty therapeutics and ENBREL(R) franchises," said Craig Parker, Immunex
senior vice president and general manager, specialty therapeutics.
Immunex Corporation is a leading biopharmaceutical company dedicated to
improving lives through immune system science innovations.
American Home Products Corporation owns a majority interest in Immunex.
AHP is one of the world's largest research-based pharmaceutical and health
care products companies. It is a leader in the discovery, development,
manufacturing and marketing of prescription drugs, including biotechnological
and vaccine products, animal health care products and over-the-counter
medications.
NOTE: This news release contains forward-looking statements that involve
risks and uncertainties, including risks associated with clinical development,
regulatory approvals, our reliance on third-party manufacturers, product
commercialization and other risks described from time to time in the SEC
reports filed by Immunex, including the most recently filed Form 10-Q. An
electronic version of this news release -- as well as additional information
about Immunex of interest to investors, customers, future employees and
patients -- is available on the Immunex home page at http://www.immunex.com.
SOURCE Immunex Corp.
 back to top
Related links:
http://www.immunex.com
Company News On-Call:
http://www.prnewswire.com/comp/434644.html or fax,
800-758-5804, ext. 434644
CONTACT:
media, Kris Greco, 206-470-4871, or
investors, Mark Leahy, 206-389-4363, both of Immunex Corporation
|
